Posted by Michael Wonder on 06 Jul 2017
Bristol-Myers Squibb’s Orencia (abatacept) receives FDA approval for treatment of active psoriatic arthritis in adults
6 July 2017 - Orencia demonstrated symptom improvement in two randomised, double-blind, placebo-controlled trials that included adult patients with psoriatic arthritis with active musculoskeletal symptoms.
Bristol-Myers Squibb announced today the U.S. FDA has approved Orencia for the treatment of adults with active psoriatic arthritis, a chronic, inflammatory disease that can affect both the skin and musculoskeletal system
Orencia is approved and available in both intravenous and subcutaneous injection formulations. Orencia should not be administered concomitantly with TNF antagonists, and is not recommended for use concomitantly with other biologic rheumatoid arthritis therapy, such as anakinra. This approval marks the third auto-immune disease indication for Orencia.
